These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15449405)

  • 1. Tailored medicine: whom will it fit? The ethics of patient and disease stratification.
    Smart A; Martin P; Parker M
    Bioethics; 2004 Aug; 18(4):322-42. PubMed ID: 15449405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics.
    van Delden J; Bolt I; Kalis A; Derijks J; Leufkens H
    Bioethics; 2004 Aug; 18(4):303-21. PubMed ID: 15449404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethical implications of pharmacogenetics--do slippery slope arguments matter?
    Schubert L
    Bioethics; 2004 Aug; 18(4):361-78. PubMed ID: 15449407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ethics of pharmacogenomics.
    Neil D; Craigie J
    Monash Bioeth Rev; 2004 Apr; 23(2):9-20. PubMed ID: 15810202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racializing drug design: implications of pharmacogenomics for health disparities.
    Lee SS
    Am J Public Health; 2005 Dec; 95(12):2133-8. PubMed ID: 16257939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics, ethics, and public policy.
    Peterson-Iyer K
    Kennedy Inst Ethics J; 2008 Mar; 18(1):35-56. PubMed ID: 18561577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race, distributive justice and the promise of pharmacogenomics: ethical considerations.
    Lee SS
    Am J Pharmacogenomics; 2003; 3(6):385-92. PubMed ID: 14672519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and moral challenges of pharmacogenomics.
    Issa AM
    Natl Cathol Bioeth Q; 2001; 1(4):541-53. PubMed ID: 12854555
    [No Abstract]   [Full Text] [Related]  

  • 10. Clustering humans: on biological boundaries.
    Lorusso L; Boniolo G
    Stud Hist Philos Biol Biomed Sci; 2008 Mar; 39(1):163-70. PubMed ID: 18331963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics and the challenge of health disparities.
    Lee SS
    Public Health Genomics; 2009; 12(3):170-9. PubMed ID: 19204420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics: questions and concerns.
    Mahlknecht U; Voelter-Mahlknecht S
    Curr Med Res Opin; 2005 Jul; 21(7):1041-7. PubMed ID: 16004671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethics and policy perspectives on personalized medicine in the post-genomic era.
    Landon MR
    J Biolaw Bus; 2005; 8(3):28-36. PubMed ID: 16459425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhetoric and hype: where's the 'ethics' in pharmacogenomics?
    Williams-Jones B; Corrigan OP
    Am J Pharmacogenomics; 2003; 3(6):375-83. PubMed ID: 14672518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics--legal, ethical and regulatory considerations.
    March R; Cheeseman K; Doherty M
    Pharmacogenomics; 2001 Nov; 2(4):317-27. PubMed ID: 11722282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical considerations on pharmacogenomics.
    Mordini E
    Pharmacol Res; 2004 Apr; 49(4):375-9. PubMed ID: 15202517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applying the genome to national drug formulary policy in the developing world.
    Roederer MW; McLeod HL
    Pharmacogenomics; 2010 May; 11(5):633-6. PubMed ID: 20415551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethical, social and legal implications of pharmacogenomics: a critical review.
    Moldrup C
    Community Genet; 2001; 4(4):204-14. PubMed ID: 12751484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Harvard case of Xu Xiping: exploitation of the people, scientific advance, or genetic theft?
    Sleeboom M
    New Genet Soc; 2005 Apr; 24(1):57-78. PubMed ID: 16552917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ethical implications of stratifying by race in pharmacogenomics.
    Lee SS
    Clin Pharmacol Ther; 2007 Jan; 81(1):122-5. PubMed ID: 17186010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.